High genomic-based predicted strain coverage among invasive meningococcal isolates when combining Bexsero and Trumenba vaccines
Open Access
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Distribution of Bexsero® Antigen Sequence Types (BASTs) in invasive meningococcal disease isolates: Implications for immunisationVaccine, 2016
- Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba®)Postgraduate Medicine, 2016
- Case Report: Benefits and Challenges of Long-term Eculizumab in Atypical Hemolytic Uremic SyndromePediatrics, 2015
- MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccineVaccine, 2015
- Evolving meningococcal immunization strategiesExpert Review of Vaccines, 2014
- Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trialThe Lancet, 2014
- Meningococcal disease and the complement systemVirulence, 2013
- The burden and impact of severe and long-term sequelae of meningococcal diseaseExpert Review of Anti-infective Therapy, 2013
- The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: Immunological, functional and structural characterization of the antigensVaccine, 2012
- An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues.The Journal of Immunology, 1987